Bullous pemphigoid: Therapeutic algorithm and practical management

Expert Opinion on Orphan Drugs

Volumn 1, Issue 5, 2013, Pages 405-412

  Daniel, Benjamin S ^a,b   Murrell, Dedee F ^a,b   Borradori, Luca ^c  

^a ST GEORGE HOSPITAL   (Australia)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

^c UNIVERSITY OF BERN   (Switzerland)

Author keywords

Autoimmune bullous disease; Bullous pemphigoid; Management; Therapy

Indexed keywords

ANTIHISTAMINIC AGENT; ANTIPRURITIC AGENT; AUTOANTIBODY; AZATHIOPRINE; CHLORAMBUCIL; CORTICOSTEROID; CYCLOSPORIN; DAPSONE; IMMUNOGLOBULIN; IMMUNOSUPPRESSIVE AGENT; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NICOTINAMIDE; NONSTEROID ANTIINFLAMMATORY AGENT; OMALIZUMAB; PREDNISOLONE; PROTON PUMP INHIBITOR; RITUXIMAB; STEROID; TETRACYCLINE DERIVATIVE; VITAMIN D;

ALGORITHM; AUTOIMMUNE DISEASE; BLISTER; BONE MARROW SUPPRESSION; BULLOUS PEMPHIGOID; CEREBROVASCULAR DISEASE; CLINICAL FEATURE; DEMENTIA; DISEASE ASSOCIATION; ENZYME LINKED IMMUNOSORBENT ASSAY; EPILEPSY; EXUDATE; HUMAN; IMMUNOFLUORESCENCE; LUPUS ERYTHEMATOSUS; MICROSCOPY; MORTALITY; MULTIPLE SCLEROSIS; NEUROLOGIC DISEASE; PARKINSON DISEASE; PLASMAPHERESIS; PRACTICE GUIDELINE; PROGNOSIS; PRURITUS; PSORIASIS; PUNCH BIOPSY; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RHEUMATOID ARTHRITIS; RISK FACTOR; SCHIZOPHRENIA; SPINE FRACTURE; VITAMIN DEFICIENCY;

EID: 84896704689     PISSN: None     EISSN: 21678707     Source Type: Journal    
DOI: 10.1517/21678707.2013.794693     Document Type: Review

References (73)

1. Jung M, Kippes W, Messer G, et al. Increased risk of bullous pemphigoid in male and very old patients: a population-based study on incidence. J Am Acad Dermatol 1999;41(2 Pt 1):266-8
2. Marazza G, Pham HC, Scharer L, et al. Incidence of bullous pemphigoid and pemphigus in Switzerland: a 2-year prospective study. Br J Dermatol 2009;161(4):861-8
3. Korman N. Bullous pemphigoid. J Am Acad Dermatol 1987;16(5 Pt 1):907-24
4. Langan SM, Smeeth L, Hubbard R, et al. Bullous pemphigoid and pemphigus vulgaris--incidence and mortality in the UK: population based cohort study. BMJ 2008;337:a180
5. Bernard P, Vaillant L, Labeille B, et al. Incidence and distribution of subepidermal autoimmune bullous skin diseases in three French regions. Bullous Diseases French Study Group. Arch Dermatol 1995;131(1):48-52
6. Schmidt E, della Torre R, Borradori L. Clinical features and practical diagnosis of bullous pemphigoid. Dermatol Clin 2011;29(3):427-38; viii-ix
7. Joly P, Baricault S, Sparsa A, et al. Incidence and mortality of bullous pemphigoid in France. J Invest Dermatol 2012;132(8):1998-2004
8. Waisbourd-Zinman O, Ben-Amitai D, Cohen AD, et al. Bullous pemphigoid in infancy: clinical and epidemiologic characteristics. J Am Acad Dermatol 2008;58(1):41-8
9. Chimanovitch I, Hamm H, Georgi M, et al. Bullous pemphigoid of childhood: autoantibodies target the same epitopes within the NC16A domain of BP180 as autoantibodies in bullous pemphigoid of adulthood. Arch Dermatol 2000;136(4):527-32
10. della Torre R, Combescure C, Cortes B, et al. Clinical presentation and diagnostic delay in bullous pemphigoid: a prospective nationwide cohort. Br J Dermatol 2012;167(5):1111-17
11. Venning VA, Taghipour K, Mohd Mustapa MF, et al. British association of Dermatologists' guidelines for the management of bullous pemphigoid 2012. Br J Dermatol 2012;167(6):1200-14
12. Taghipour K, Chi CC, Vincent A, et al. The association of bullous pemphigoid with cerebrovascular disease and dementia: a case-control study. Arch Dermatol 2010;146(11):1251-4
13. Bastuji-Garin S, Joly P, Lemordant P, et al. Risk factors for bullous pemphigoid in the elderly: a prospective case-control study. J Invest Dermatol 2011;131(3):637-43
14. Langan SM, Groves RW, West J. The relationship between neurological disease and bullous pemphigoid: a population-based case-control study. J Invest Dermatol 2011;131(3):631-6
15. Cordel N, Chosidow O, Hellot MF, et al. Neurological disorders in patients with bullous pemphigoid. Dermatology 2007;215(3):187-91
16. Chen YJ, Wu CY, Lin MW, et al. Comorbidity profiles among patients with bullous pemphigoid: a nationwide population-based study. Br J Dermatol 2011;165(3):593-9
17. Koerber WA Jr, Price NM, Watson W. Coexistent psoriasis and bullous pemphigoid: a report of six cases. Arch Dermatol 1978;114(11):1643-6
18. Marzano AV, Trevisan V, Eller-Vainicher C, et al. Evidence for vitamin D deficiency and increased prevalence of fractures in autoimmune bullous skin diseases. Br J Dermatol 2012;167(3):688-91
19. Tukaj S, Schmidt E, Recke A, et al. Vitamin D status in bullous pemphigoid patients. Br J Derm 2013;168(4):873-4
20. Chorzelski TP, Jablonska S, Maciejowska E, et al. Coexistence of malignancies with bullous pemphigoid. Arch Dermatol 1978;114(6):964
21. Stone SP, Schroeter AL. Bullous pemphigoid and associated malignant neoplasms. Arch Dermatol 1975;111(8):991-4
22. Lindelof B, Islam N, Eklund G, et al. Pemphigoid and cancer. Arch Dermatol 1990;126(1):66-8
23. Stoll DM, King LE Jr. Association of bullous pemphigoid with systemic lupus erythematosus. Arch Dermatol 1984;120(3):362-6
24. Grattan CE. Evidence of an association between bullous pemphigoid and psoriasis. Br J Dermatol 1985;113(3):281-3
25. Giannini JM, Callen JP, Gruber GG. Bullous pemphigoid and rheumatoid arthritis. J Am Acad Dermatol 1981;4(6):695-7
26. Marzano AV, Tedeschi A, Polloni I, et al. Prothrombotic state and impaired fibrinolysis in bullous pemphigoid, the most frequent autoimmune blistering disease. Clin Exp Immunol 2013;171(1):76-81
27. Savin JA. Death in bullous pemphigoid. Clin Dermatol 1987;5(1):52-9
28. Cortes B, Marazza G, Naldi L, et al. Mortality of bullous pemphigoid in Switzerland: a prospective study. Br J Dermatol 2011;165(2):368-74
29. Roujeau JC, Lok C, Bastuji-Garin S, et al. High risk of death in elderly patients with extensive bullous pemphigoid. Arch Dermatol 1998;134(4):465-9
30. Parker SR, Dyson S, Brisman S, et al. Mortality of bullous pemphigoid: an evaluation of 223 patients and comparison with the mortality in the general population in the United States. J Am Acad Dermatol 2008;59(4):582-8
31. Murrell DF, Daniel BS, Joly P, et al. Definitions and outcome measures for bullous pemphigoid: recommendations by an international panel of experts. J Am Acad Dermatol 2012;66(3):479-85
32. Kirtschig G, Middleton P, Bennett C, et al. Interventions for bullous pemphigoid. Cochrane Database Syst Rev 2010;10:CD002292
33. Hernandez-Diaz S, Rodriguez LA. Steroids and risk of upper gastrointestinal complications. Am J Epidemiol 2001;153(11):1089-93
34. Frew JW, Murrell DF. Corticosteroid use in autoimmune blistering diseases. Immunol Allergy Clin North Am 2012;32(2):283-94; vii
35. Morel P, Guillaume JC. Treatment of bullous pemphigoid with prednisolone only: 0.75 mg/kg/day versus 1.25 mg/kg/ day. A multicenter randomized study. Ann Dermatol Venereol 1984;111(10):925-8
36. Joly P, Roujeau JC, Benichou J, et al. A comparison of oral and topical corticosteroids in patients with bullous pemphigoid. N Engl J Med 2002;346(5):321-7
37. Joly P, Roujeau JC, Benichou J, et al. A comparison of two regimens of topical corticosteroids in the treatment of patients with bullous pemphigoid: a multicenter randomized study. J Invest Dermatol 2009;129(7):1681-7
38. Kolbach DN, Remme JJ, Bos WH, et al. Bullous pemphigoid successfully controlled by tetracycline and nicotinamide. Br J Dermatol 1995;133(1):88-90
39. Shiohara J, Yoshida K, Hasegawa J, et al. Tetracycline and niacinamide control bullous pemphigoid but not pemphigus foliaceus when these conditions coexist. J Dermatol 2010;37(7):657-61
40. Fivenson DP, Breneman DL, Rosen GB, et al. Nicotinamide and tetracycline therapy of bullous pemphigoid. Arch Dermatol 1994;130(6):753-8
41. Burton JL, Harman RR, Peachey RD, et al. Azathioprine plus prednisone in treatment of pemphigoid. Br Med J 1978;2(6146):1190-1
42. Greaves MW, Burton JL, Marks J, et al. Azathioprine in treatment of bullous pemphigoid. Br Med J 1971;1(5741):144-5
43. Beissert S, Werfel T, Frieling U, et al. A comparison of oral methylprednisolone plus azathioprine or mycophenolate mofetil for the treatment of bullous pemphigoid. Arch Dermatol 2007;143(12):1536-42
44. Guillaume JC, Vaillant L, Bernard P, et al. Controlled trial of azathioprine and plasma exchange in addition to prednisolone in the treatment of bullous pemphigoid. Arch Dermatol 1993;129(1):49-53
45. Gunay U, Gunduz K, Ermertcan AT, et al. Coexistence of psoriasis and bullous pemphigoid: remission with low-dose methotrexate. Cutan Ocul Toxicol 2013;32(2):168-9
46. Bara C, Maillard H, Briand N, et al. Methotrexate for bullous pemphigoid: preliminary study. Arch Dermatol 2003;139(11):1506-7
47. Kwatra SG, Jorizzo JL. Bullous pemphigoid: a case series with emphasis on long-term remission off therapy. J Dermatolog Treat 2012
48. Kjellman P, Eriksson H, Berg P. A retrospective analysis of patients with bullous pemphigoid treated with methotrexate. Arch Dermatol 2008;144(5):612-16
49. Czernik A, Bystryn JC. Improvement of intravenous immunoglobulin therapy for bullous pemphigoid by adding immunosuppressive agents: marked improvement in depletion of circulating autoantibodies. Arch Dermatol 2008;144(5):658-61
50. Harman KE, Black MM. High-dose intravenous immune globulin for the treatment of autoimmune blistering diseases: an evaluation of its use in 14 cases. Br J Dermatol 1999;140(5):865-74
51. Seidling V, Hoffmann JH, Enk AH, et al. Analysis of high-dose intravenous immunoglobulin therapy in 16 patients with refractory autoimmune blistering skin disease: high efficacy and no serious adverse events. Acta Derm Venereol 2012; Epub ahead of print
52. Roujeau JC, Guillaume JC, Morel P, et al. Plasma exchange in bullous pemphigoid. Lancet 1984;2(8401):486-8
53. London VA, Kim GH, Fairley JA, et al. Successful treatment of bullous pemphigoid with omalizumab. Arch Dermatol 2012;148(11):1241-3
54. Gurcan HM, Ahmed AR. Efficacy of dapsone in the treatment of pemphigus and pemphigoid: analysis of current data. Am J Clin Dermatol 2009;10(6):383-96
55. Schmidt E, Kraensel R, Goebeler M, et al. Treatment of bullous pemphigoid with dapsone, methylprednisolone, and topical clobetasol propionate: a retrospective study of 62 cases. Cutis 2005;76(3):205-9
56. Bouscarat F, Chosidow O, Picard-Dahan C, et al. Treatment of bullous pemphigoid with dapsone: retrospective study of thirty-six cases. J Am Acad Dermatol 1996;34(4):683-4
57. Milligan A, Hutchinson PE. The use of chlorambucil in the treatment of bullous pemphigoid. J Am Acad Dermatol 1990;22(5 Pt 1):796-801
58. Chave TA, Mortimer NJ, Shah DS, et al. Chlorambucil as a steroid-sparing agent in bullous pemphigoid. Br J Dermatol 2004;151(5):1107-8
59. Cortes B, Khelifa E, Clivaz L, et al. Mortality rate in bullous pemphigoid: a retrospective monocentric cohort study. Dermatology 2012;225(4):320-5
60. Thivolet J, Barthelemy H, Rigot-Muller G, et al. Effects of cyclosporin on bullous pemphigoid and pemphigus. Lancet 1985;1(8424):334-5
61. Venning VA, Millard PR, Wojnarowska F. Dapsone as first line therapy for bullous pemphigoid. Br J Dermatol 1989;120(1):83-92
62. Chu J, Bradley M, Marinkovich MP. Topical tacrolimus is a useful adjunctive therapy for bullous pemphigoid. Arch Dermatol 2003;139(6):813-15
63. Curley RK, Holden CA. Steroid-resistant bullous pemphigoid treated with cyclosporin A. Clin Exp Dermatol 1991;16(1):68-9
64. Itoh T, Hosokawa H, Shirai Y, et al. Successful treatment of bullous pemphigoid with pulsed intravenous cyclophosphamide. Br J Dermatol 1996;134(5):931-3
65. Dawe RS, Naidoo DK, Ferguson J. Severe bullous pemphigoid responsive to pulsed intravenous dexamethasone and oral cyclophosphamide. Br J Dermatol 1997;137(5):826-7
66. Reguiai Z, Tchen T, Perceau G, et al. Efficacy of rituximab in a case of refractory bullous pemphigoid. Ann Dermatol Venereol 2009;136(5):431-4
67. Kasperkiewicz M, Shimanovich I, Ludwig RJ, et al. Rituximab for treatment-refractory pemphigus and pemphigoid: a case series of 17 patients. J Am Acad Dermatol 2011;65(3):552-8
68. Schulze J, Bader P, Henke U, et al. Severe bullous pemphigoid in an infant--successful treatment with rituximab. Pediatr Dermatol 2008;25(4):462-5
69. Daniel BS, Borradori L, Hall RP III, et al. Evidence-based management of bullous pemphigoid. Dermatol Clin 2011;29(4):613-20
70. Joly P, Benichou J, Saiag P, et al. Response to: mortality rate of bullous pemphigoid in a US medical center. J Invest Dermatol 2005;124(3):664-5
71. Garcia-Doval I, Conde Taboada A, Cruces Prado MJ. Sepsis associated with dermatologic hospitalization is not the cause of high mortality of bullous pemphigoid in Europe. J Invest Dermatol 2005;124(3):666-7
72. Rzany B, Partscht K, Jung M, et al. Risk factors for lethal outcome in patients with bullous pemphigoid: low serum albumin level, high dosage of glucocorticosteroids, and old age. Arch Dermatol 2002;138(7):903-8
73. Bernard P, Reguiai Z, Tancrede-Bohin E, et al. Risk factors for relapse in patients with bullous pemphigoid in clinical remission: a multicenter, prospective, cohort study. Arch Dermatol 2009;145(5):537-42